Afimmune Confirm Alignment with FDA on Planned Pivotal Trial of Epeleuton in Sickle Cell Disease Patients
January 4, 2023Data Showing Epeleuton Reduces Endothelial Adhesion Of Red Blood Cells From Sickle Cell Disease Patients Will Be Presented At The EHA 2023 Congress
June 5, 2023Afimmune to Host KOL Webinar on Sickle Cell Disease: The Changing Landscape and Need for New Treatments
Dublin, Ireland, 29 Mar 2023: Afimmune, a privately held, clinical stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced it will host a key opinion leader (KOL) webinar on Sickle Cell Disease (SCD) on April 12, 2023 at 9:00 Eastern Time / 14:00 GMT.
The expert panel discussion will feature KOLs Biree Andemariam, MD (University of Connecticut; Sickle Cell Disease Association of America) and Vivien Sheehan, MD, PhD (Emory University) who will discuss the treatment landscape and large unmet medical need in treating patients who suffer from SCD.
The event will also feature an update from Afimmune on their clinical development plans for Epeleuton, a novel synthetic fatty acid drug product which has been shown to have a unique dual mechanism of action for the treatment of SCD, targeting factors affecting severity, course of disease, and vaso-occlusive crisis risk.
Epeleuton has received orphan drug designation for the treatment of SCD from the FDA and EMA.
A live question and answer session will follow the formal presentations. To register for the event, please click here.
About Epeleuton
Epeleuton is 15-hydroxy eicosapentaenoic acid (15(S)-HEPE) ethyl ester, a novel synthetic fatty acid drug product. Afimmune is prioritizing Epeleuton for SCD due to its superior preclinical efficacy, first-in-class opportunity and a significantly reduced regulatory pathway. Epeleuton has received orphan drug designation for the treatment of SCD from the FDA and EMA.
About Sickle Cell Disease
SCD is a group of inherited, progressive blood disorders carried by the β allele of the hemoglobin gene with an expected 30-year reduced life expectancy. The disease is characterized by abnormal polymerization of hemoglobin during oxygenation which results in the sickling of red blood cells. The disease is rare, with an estimated prevalence of only ~100,000 people affected in the US and ~52,000 people in the EU.
About Afimmune
Afimmune, headquartered in Dublin, Ireland, is a clinical stage drug discovery and development company working on new medicines to improve the quality of life for people with rare and inflammatory diseases.
Contact
[email protected]